Bavarian Nordic to acquire Vivotif and Vaxchora travel vaccines from Emergent BioSolutions
Bavarian Nordic A/S will acquire two oral vaccines from Emergent BioSolutions for a total consideration of up to $380 million, to strengthen its position in ... Read More
Vanda Pharmaceuticals gets FDA orphan drug status for VPO-227 in cholera
Vanda Pharmaceuticals has secured orphan drug designation for VPO-227 from the US Food and Drug Administration (FDA) for the treatment of cholera. According to the ... Read More